Table 4.

Correlation analysis of PFS-related radiomics signature with clinical parameters

Variables	Development cohort (n = 145)			Validation cohort (n = 51)
	Low Rad-score group	High Rad-score group	P	Low Rad-score group	High Rad-score group	P
Gender			0.963			0.424
Male	45	32		18	11
Female	40	28		16	6
Age, years			0.283			1.000
≤ 60	28	25		12	6
> 60	57	35		22	11
Tumor location			0.021			0.046
head	78	47		30	11
body and tail	7	13		4	6
Maximum diameter of tumor			0.469			0.428
≤ 4 cm	56	36		18	7
> 4 cm	29	24		16	10
Differentiated degree			< 0.001			0.015
High	15	0		7	0
Medium	59	33		22	9
Low	11	27		5	8
AJCC staging			< 0.001			0.038
I	21	2		7	0
II	57	39		24	12
III	7	19		3	5
T staging			0.737			0.582
T1	14	10		5	1
T2	42	26		13	6
T3	29	24		16	10
N staging			0.002			0.084
N0	35	14		14	3
N1	42	27		17	9
N2	8	19		3	5
Vascular invasion			0.006			0.318
No	51	22		21	8
Yes	34	38		13	9
Nerve invasion			0.070			0.003
No	47	24		25	5
Yes	38	36		9	12
BMI (Kg/m2)			0.106			1.000
< 24	47	25		18	9
≥ 24	38	35		16	8
CEA (ng/ml)			0.459			0.229
≤ 5	23	13		9	2
> 5	62	47		25	15
CA19-9 (U/ml)			0.011			0.320
≤ 37	45	19		17	6
> 37	40	41		17	11
Smoking history			0.849			0.294
No	64	46		21	13
Yes	21	14		13	4
Drinking history			0.916			0.834
No	63	44		23	11
Yes	22	16		11	6
Hypertension			0.358			0.824
No	60	38		25	12
Yes	25	22		9	5
Diabetes			1.000			0.375
No	68	48		26	11
Yes	17	12		8	6
Clinical symptoms			0.333			0.739
No	6	2		3	2
Yes	79	58		31	15
Recurrence and/or metastasis			< 0.001			0.019
No	69	31		27	8
Yes	16	29		7	9